Literature DB >> 21397718

Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines.

Janny Westdijk1, Debbie Brugmans, Javier Martin, Aart van't Oever, Wilfried A M Bakker, Lonneke Levels, Gideon Kersten.   

Abstract

GMP-batches of Sabin-IPV were characterized for their antigenic and immunogenic properties. Antigenic fingerprints of Sabin-IPV reveal that the D-antigen unit is not a fixed amount of antigen but depends on antibody and assay type. Instead of the D-antigen unit we propose standardization of IPV based on a combination of protein amount for dose and D-antigenicity for quality of the vaccine. Although Sabin-IPV type 2 is less immunogenic than regular wild type IPV type 2, the immunogenicity (virus neutralizing titers) per microgram antigen for Sabin-IPV type 2 is in the same order as for wild type serotypes 1 and 3. The latter observations are in line with data from human trials. This suggests that a higher dose of Sabin-IPV type 2 to compensate for the lower rat immunogenicity may not be necessary.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21397718     DOI: 10.1016/j.vaccine.2011.02.085

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

Review 1.  Biosensor binding data and its applicability to the determination of active concentration.

Authors:  Robert Karlsson
Journal:  Biophys Rev       Date:  2016-10-17

2.  Real-time and Label-free Bio-sensing of Molecular Interactions by Surface Plasmon Resonance: A Laboratory Medicine Perspective.

Authors:  Erik Helmerhorst; David J Chandler; Matt Nussio; Cyril D Mamotte
Journal:  Clin Biochem Rev       Date:  2012-11

3.  Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats.

Authors:  Koen van der Maaden; Sebastiaan J Trietsch; Heleen Kraan; Eleni Maria Varypataki; Stefan Romeijn; Raphäel Zwier; Heiko J van der Linden; Gideon Kersten; Thomas Hankemeier; Wim Jiskoot; Joke Bouwstra
Journal:  Pharm Res       Date:  2014-01-28       Impact factor: 4.200

4.  Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.

Authors:  Janny Westdijk; Patrick Koedam; Mario Barro; Benjamin P Steil; Nicolas Collin; Thomas S Vedvick; Wilfried A M Bakker; Peter van der Ley; Gideon Kersten
Journal:  Vaccine       Date:  2013-01-09       Impact factor: 3.641

5.  Development of thermostable lyophilized inactivated polio vaccine.

Authors:  Heleen Kraan; Paul van Herpen; Gideon Kersten; Jean-Pierre Amorij
Journal:  Pharm Res       Date:  2014-04-24       Impact factor: 4.200

6.  Incompatibility of lyophilized inactivated polio vaccine with liquid pentavalent whole-cell-pertussis-containing vaccine.

Authors:  Heleen Kraan; Rimko Ten Have; Larissa van der Maas; Gideon Kersten; Jean-Pierre Amorij
Journal:  Vaccine       Date:  2016-07-26       Impact factor: 3.641

7.  Development of Stabilizing Formulations of a Trivalent Inactivated Poliovirus Vaccine in a Dried State for Delivery in the Nanopatch™ Microprojection Array.

Authors:  Ying Wan; John M Hickey; Christopher Bird; Katey Witham; Paul Fahey; Angus Forster; Sangeeta B Joshi; David B Volkin
Journal:  J Pharm Sci       Date:  2018-02-06       Impact factor: 3.534

8.  An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.

Authors:  Viki Bockstal; Machteld M Tiemessen; Rogier Achterberg; Carlo Van Wordragen; Ad M Knaapen; Jan Serroyen; Wilfred E Marissen; Hanneke Schuitemaker; Roland Zahn
Journal:  Vaccine       Date:  2018-10-09       Impact factor: 3.641

9.  Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals.

Authors:  Yvonne E Thomassen; Aart G van 't Oever; Monique G C T van Oijen; René H Wijffels; Leo A van der Pol; Wilfried A M Bakker
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

10.  Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine.

Authors:  Barbara P Sanders; Isabel de Los Rios Oakes; Vladimir van Hoek; Viki Bockstal; Tobias Kamphuis; Taco G Uil; Yutong Song; Gillian Cooper; Laura E Crawt; Javier Martín; Roland Zahn; John Lewis; Eckard Wimmer; Jerome H H V Custers; Hanneke Schuitemaker; Jeronimo Cello; Diana Edo-Matas
Journal:  PLoS Pathog       Date:  2016-03-31       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.